Navigation Links
ADVENTRX Provides Update on Strategic Transaction Process
Date:2/10/2009

r partnering transaction or raise sufficient capital to fund the projects necessary to meet its goals, including funding the continued development and commercialization of ANX-530 or ANX-514; the risk that the Company's recent cost-containment measures, as well as any future workforce reductions and/or reductions/delays in spending, will further impact the Company's development and commercialization plans, including its ability to achieve on time its previously stated goals; the risk that the departure of the Company's former Chief Executive Officer and President and Executive Vice President and Chief Financial Officer and/or ADVENTRX's leadership by a committee of executive officers will negatively impact ADVENTRX's ability to execute its business plan or to maintain effective disclosure controls and procedures or internal control over financial reporting; the risk the FDA will determine that ANX-530 and Navelbine are not bioequivalent, including as a result of performing pharmacokinetic equivalence analysis based a patient population other than the population on which ADVENTRX based its analysis; the risk that the bioequivalence study of ANX-514 does not demonstrate pharmacokinetic equivalence or bioequivalence to Taxotere; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence study, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530 and ANX- 514, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-514; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings, including prior to the submission or
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... 11, 2014 Central Florida board-certified veterinary ... partnerships with several Brevard County animal hospitals to bring ... been working in the area since January 2006, credentialed ... 2008, and is happy to now offer his expertise ... Christiansen has used stem cell therapy with Vet-Stem, Inc. ...
(Date:9/11/2014)... The Remedy Group , a retained ... organizations, has announced that Terry Souwannamuang has joined the ... in biopharma and managed care Terry steadily rose in ... brand new specialty pharmacy for a Portland-based managed care ... Terry has a Bachelor’s Degree in General Science with ...
(Date:9/10/2014)... BASEL , Schweiz, September 11, 2014 ... Register für Eierstockkrebs, die bei der Jahresversammlung ... vorgestellt wurden, bekräftigen die komplette Tumorprofilierung als ... Bericht von Caris Registry™ zeigte ein deutlich ... mit Eierstock-, Eileiter- oder primär peritonealem Krebs, ...
(Date:9/10/2014)... -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), a ... host a conference call and webcast tomorrow, September 11, ... time). The live call may be accessed ... participant code 38075452. The webcast can be accessed live ... site at www.orexigen.com and will be archived ...
Breaking Biology Technology:Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 2Dr. Jeff Christiansen is Now Offering Stem Cell Therapy for Pets at Five Brevard County Animal Hospitals and Beyond 3The Remedy Group Announces Hiring of Managed Care and Specialty Pharmacy Veteran 2Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 2Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 3Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 4Verbesserte Überlebensrate von Patientinnen mit Eierstockkrebs, die Behandlungen nach Anleitung durch komplette Tumorprofilierung erhalten 5
... biomass and enzymes to produce hydrogen fuel, ethanol, and ... AgVest in Lake Delton last Thursday. , ,These ... the conference by the AgVest group, which focuses on ... specific recommendations, AgVest tries to hook up up-and-coming agricultural ...
... a PeopleSoft database for tracking alumni in favor ... used for 12 years. , ,Schools and colleges can access ... based on a database from 4D, Inc. , ... separate from the university. When the central database failed to ...
... has been less than overwhelming to Governor Jim Doyles ... private money in Wisconsins biotechnology future. Budget-conscious members of ... of stem-cell research have once again protested, and Milwaukee ... of Madison. , ,Doyle should address all legitimate gripes ...
Cached Biology Technology:Investors hear about new agricultural technology 2Alumni Association extends database help to university 2Alumni Association extends database help to university 3Wisconsin cannot afford to take a pass on Doyles biotech plan 2Wisconsin cannot afford to take a pass on Doyles biotech plan 3
(Date:9/11/2014)... treatise "Flora of Northumberland and Durham" by Nathaniel ... Books platform as an example of combining modern ... new sort of resource and data re-use. This publication ... the region, which can be seen as a model ... enriched re-publication marries the meticulous detail of old ...
(Date:9/11/2014)... Northeastern University researchers and their international colleagues have ... role of neutral evolution in the biogeographic distribution ... Thursday in the journal Science . The ... a neutral agent-based model"was co-authored by Ferdi Hellweger, ... of civil and environmental engineering; his doctoral student ...
(Date:9/11/2014)... -- Today at the TEDMED conference, Tute Genomics announced ... genome sequencing results at the fingertips of the individual ... The $1000 was announced earlier this year by Illumina, ... point towards widespread adoption of genome sequencing in research ... million variants per human genome, data analysis has become ...
Breaking Biology News(10 mins):Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 2Re-publication of 'Flora of Northumberland and Durham' (1831): A dramatic account of change 3Microbes evolve faster than ocean can disperse them 2Tute Genomics Launches MyGene Portal for Genome-guided Medicine 2Tute Genomics Launches MyGene Portal for Genome-guided Medicine 3
... Jan. 26, 2011 TGen Drug Development (TD2) ... should help speed new drugs safely into human testing ... Scottsdale, Ariz., provides drug development firms with expertise in ... regulatory approval steps of getting new drugs to patients ...
... ribbon worm discovered in Kosterhavet National Park in 2007 ... Pseudomicrura afzelii , a form of nemertean or ... at the University of Gothenburg, Sweden, using DNA technology. ... from the traditional, highly labour-intensive way of describing a ...
... 25, 2011Give caffeine to cells engineered to produce viruses used ... 8-times more virus, according to a paper published in ... Ann Liebert, Inc. ( www.liebertpub.com ). The paper is available ... inexpensive strategy for increasing lentivirus production was developed by Brian ...
Cached Biology News:Arizona companies team up, providing quick development of cancer drugs 2Researchers register new species using DNA-based description 2
MBS 384 well satellite block unit with height adjusting heated lid, 384 well block holds 1 x 0.04 ml 384 well plate...
384 well block MBSr. Robot compatible block ejection mechanism. Stackable. (384 well block - holds 384 well plate)...
...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Biology Products: